Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Rhenium-186

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Plus Therapeutics Introduces Reyobiq as FDA-Accepted Name
    Plus Therapeutics Introduces Reyobiq as FDA-Accepted Name

    20 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/20/3046120/0/en/Plus-Therapeutics-Introduces-REYOBIQ-FDA-Accepted-Proprietary-Name-for-Lead-Drug-Candidate.html

    GLOBENEWSWIRE
    20 Mar 2025
    Share Share
    Plus Publishes Ph1 Rhenium-186 Data In Glioblastoma In Nature
    Plus Publishes Ph1 Rhenium-186 Data In Glioblastoma In Nature

    07 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/07/3038883/0/en/Plus-Therapeutics-Announces-Peer-Reviewed-Publication-in-Nature-Communications-Highlighting-Promising-Phase-1-Results-for-Rhenium-186Re-Obisbemeda-in-Glioblastoma.html

    GLOBENEWSWIRE
    07 Mar 2025
    Share Share
    Plus Therapeutics Gets FDA Orphan Drug Nod For Rhenium-186 In Lung Mets
    Plus Therapeutics Gets FDA Orphan Drug Nod For Rhenium-186 In Lung Mets

    06 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/06/3038083/0/en/Plus-Therapeutics-Granted-U-S-FDA-Orphan-Drug-Designation-for-Rhenium-186Re-Obisbemeda-for-the-Treatment-of-Leptomeningeal-Metastases-in-Patients-with-Lung-Cancer.html

    GLOBENEWSWIRE
    06 Mar 2025
    Share Share
    Plus Therapeutics to Present Data from ReSPECT-GBM Clinical Trial
    Plus Therapeutics to Present Data from ReSPECT-GBM Clinical Trial

    23 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/23/2502803/0/en/Plus-Therapeutics-to-Present-Data-from-ReSPECT-GBM-Clinical-Trial-at-the-European-Society-for-Medical-Oncology-Congress-2022.html

    GLOBENEWSWIRE
    23 Aug 2022
    Share Share
    Plus Therapeutics Reports Commercial Manufacturing Supply Deal for Its Lead Drug
    Plus Therapeutics Reports Commercial Manufacturing Supply Deal for Its Lead Drug

    01 Sep 2021

    // BIO SPACE

    https://www.biospace.com/article/releases/plus-therapeutics-announces-commercial-manufacturing-supply-agreement-for-its-lead-investigational-drug/

    BIO SPACE
    01 Sep 2021
    Share Share